By a News Reporter-Staff News Editor at Marketing Business Weekly Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that the Dutch Inspectie voor de Gezondheidszorg has granted marketing authorization in the Netherlands to...
GlycoMimetics recently reported that the University of Michigan has dosed the first healthy volunteer in a Phase 1 clinical trial of GMI-1271, a novel and proprietary E-selectin antagonist. The U-M study of our drug candidate as a potential treatment for a serious blood- clotting disorder is an important example of a potential additional indication
Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi, an oral medication, is the first and only product approved by the FDA for PV, a rare and progressive blood cancer.
Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. In a release, the Company noted that PV is a rare and progressive blood cancer. For the first time we are able to provide these pa
According to a release from Jazz Pharmaceuticals, Xyrem is the only U.S. Food and Drug Administration approved treatment for narcolepsy with cataplexy in adults. "Narcolepsy with cataplexy is a debilitating, chronic condition that commonly begins in childhood, yet there are no approved cataplexy treatments for patients under the age of 18," said J
Mylan recently reported that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. Dominique Limet, CEO ViiV Healthcare commented
"By working closely with the OCTC network, we at PacificGMP believe that our clients will be able to complete their clinical trials faster and more quickly, thus bringing needed therapies, vaccines, and diagnostics to the public," said Gary Pierce, the Chief Executive Officer and General Counsel of PacificGMP. PacificGMP's client pool is largely th
SAB Biotherapeutics, a biopharmaceutical development company, recently teamed with the U.S. Army Medical Research Institute of Infectious Diseases to address the potentially deadly hantavirus using a novel approach to developing protective antibodies against it. Hantaviruses cause a condition known as Hantavirus Pulmonary Syndrome, which has a case
Seattle Genetics and Takeda Pharmaceutical Company Limited recently reported data demonstrating that Hodgkin lymphoma patients at risk of relapse following an autologous stem cell transplant who received Adcetris as consolidation therapy immediately after ASCT had significant improvement in progression-free survival compared to patients who...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Data detailed on Public Policy have been presented. For more information on this research see: Principles in Action: An Examination of Food and Drug Administration Letters Involving Violative Internet Promotions from 1997 to 2012. Journal of Public Policy& Marketing, 2014; 33:
Sunovion Pharmaceuticals recently reported that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration seeking approval for the use of Aptiom as monotherapy treatment of partial-onset seizures. "Sunovion has a deep commitment to helping address the unmet medical needs of people living with partial-onset seizu
UCB Inc., the U.S.-based subsidiary of UCB S.A. with Headquarter in Belgium, has recently completed the deployment of Cegedim's Customer Relationship Management, Mobile Intelligence and Closed Loop Marketing on Apple's iPad devices, which has allowed for consolidation from three separately sourced applications to one integrated multichannel platfor
MADRID- Generic drug maker Actavis plc is considering Spanish drugmaker Almirall SA as one of several possible takeover targets, Bloomberg reported citing people familiar with the matter said. The report said that Actavis has identified Almirall, which could be valued at about 3 billion euros or $3.7 billion in a deal, as one of its preferred targe
By a News Reporter-Staff News Editor at Marketing Weekly News Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that the Dutch Inspectie voor de Gezondheidszorg has granted marketing authorization in the Netherlands to ILUVIEN.
The Aim-listed business is moving its operation from London to Cardiff after successfully raising Pounds 14 m in March through a new equity placing- with the cornerstone investor being the Welsh Government's Welsh Life Sciences Investment Fund. The company has incorporated Verona Pharma Inc and also announced the appointment of Kenneth Newman to th
A RAPIDLY growing pharmaceutical and healthcare products firm has become the latest business to move into a new multi-million pound development at a Derbyshire marina. Bionical has taken offices at the Boardwalk, a Pounds 1.7 million scheme at Mercia Marina, near Willington. Yesterday, Secretary of State for Transport and Derbyshire Dales MP Patric
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, announced that it received de novo clearance from the U.S. Food and Drug Administration for its FFRCT technology. HeartFlow FFRCT is the first and only non-invasive imaging technology for
Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze . "Administration of Erwinaze through an intravenous infusion provides physicians another option for patients, including those who cannot tolerate intramuscular injections," said Jeffrey Tobias, M.D., executiv
By a News Reporter-Staff News Editor at Marketing Weekly News MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced the election of Kevan E. Clemens, Ph.D., to its Board of Directors at the Company's Annual Meeting of Stockholders yesterday. His election increases the size of MEI Pharma
DALLAS, Dec. 20, 2014/ PRNewswire-iReach/ The global pharmaceutical excipients market is expected to grow at a CAGR of 6.7% during the forecast period of 2014 to 2019. Swellingutilization of parenteral products owing to rise in the global burden of chronic and lifestyle diseases and heavy investments by the pharmaceutical industry on the developm
The meeting was attended by Muhammad Mansoor Dilawar, Khawaj Shahzeb Akram, Ejaz Ahmed Siddiqui, Akbar Ali Bhatti, Uzair Nagra, Khalid Munir, Dr. Zulfiqar Malik, Shafique Abbasi, Dr. Tahir Azam, Shahensah Riasat, Mubashar Javaid, Abid Ali Jawa, Ch. Yousaf Ali, Haseeb Khan, Aamir Saleem Butt, Adeel Haider and other owners of pharma industry.
The Pakistan Pharmaceutical Manufacturing Association criticised Punjab Health Department on Friday for taking action against two pharmaceutical companies. Many illegal actions were taken that day including sample collection, compiling a report, calling an urgent meeting of the Provincial Quality Control Board and making unilateral decisions.
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK?, an all-oral, interferon-free treatment, with or without ribavirin, for the treatment of patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis. "We are proud of the work of our research and development organization to bri
Dublin- Research and Markets has announced the addition of the "Acne Vulgaris- Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action, route o
Actavis plc, a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston, MA.. The presentation will take place on Tuesday, January 6, 2015 at 12:00 PM Eastern